CC
JUNO

Clearline Capital’s Juno Therapeutics, Inc. JUNO Stock Holding History

Clearline Capital’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-116,200
Closed -$2.19M – 77
2016
Q4 		$2.19M Buy
+116,200
New +$2.84M 0.99% 28

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Clearline Capital's JUNO Position: Q1 2017 in Review

Clearline Capital sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 116,200 shares — an estimated $2.19M sold.

Clearline Capital first reported a position in JUNO in Q4 2016 and held it in 1 quarter. The position peaked at $2.19M in Q4 2016. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

  • Clearline Capital reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Clearline Capital sold 116,200 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $2.19M.
  • Clearline Capital first reported a position in Juno Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Clearline Capital's Juno Therapeutics, Inc. position peaked at $2.19M in Q4 2016.
  • 157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on Clearline Capital's 13F filing for Q1 2017, filed 12 May 2017.